Navigation Links
NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Date:7/31/2009

SAN MATEO, Calif., July 31 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, August 7, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its second quarter 2009.

The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning August 7, 2009 at 12:00 p.m. ET (9:00 a.m. PT) and ending on August 17, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 329620. A replay of the webcast will also be available on the corporate website for one month, through September 7, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza((TM)), a dermal patch designed to manage pain associated with peripheral neuropathi
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Added to Russell 3000 Index
2. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
3. NeurogesX to Present at Needham Life Sciences Conference
4. NeurogesX Receives European Commission Approval for Qutenza(TM)
5. NeurogesX Reports First Quarter 2009 Results
6. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
7. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
8. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
9. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
10. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
11. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of ... fields of cartilage repair, regeneration, allograft reconstruction and ... around the world gathered to discuss the future ... Institute of Regenerative Medicine symposium, Cartilage Regeneration: ... Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, and ...
(Date:9/29/2014)... 2014 Research and Markets  has announced ... Analyzer, and Gas Chromatograph Market by Type , Technology, ... Trends & Forecast to 2013 - 2020" report ... is a process analytical instrument that provides chemical composition ... the way by which companies carry out their production ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4
... 4 Karolinska Development (publ),today announced that one of ... study of its candidate drug, tafoxiparin, a,new drug substance ... results of the Phase II trial bring the project ... , Dilafor,s candidate drug, tafoxiparin ...
... Va. (Sept. 1, 2009) An international team of ... acts as a semiconductor and could help material scientists ... The team of researchers from Virginia Commonwealth University; ... Science in Shanghai, China; and Tohoku University in Sedai, ...
... Sept. 3 Kendle (Nasdaq: KNDL ), a ... will participate in the upcoming Robert Baird 2009 Health Care ... New York in New York City. , , ... , Kendle,s formal presentation will be given by ...
Cached Biology Technology:Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3Researchers design new graphene-based, nanomaterial with magnetic properties 2Kendle to Present at Robert Baird 2009 Health Care Conference 2
(Date:9/28/2014)... findings by scientists at the University of California, Santa ... elements within the genomes of primates drove the evolution ... genes in every cell of our bodies. , ... as "retrotransposons" (a.k.a. "jumping genes") and the genes that ... researchers have, for the first time, identified genes in ...
(Date:9/27/2014)... expression levels of an enzyme involved in DNA synthesis ... certain treatments, a Korean study has shown at the ... phase II study, researchers showed that patients whose lung ... synthase experienced a greater benefit from treatment with the ... expressed high levels. , "Thymidylate synthase is one ...
(Date:9/27/2014)... and body mass in patients with advanced lung cancer ... phase III data presented at the ESMO 2014 Congress ... are among the most troubling and distressing symptoms of ... the study,s principal investigator, Dr Jennifer Temel from the ... Symptoms of the wasting syndrome can include a loss ...
Breaking Biology News(10 mins):Human genome was shaped by an evolutionary arms race with itself 2Human genome was shaped by an evolutionary arms race with itself 3Human genome was shaped by an evolutionary arms race with itself 4Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies 2Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies 3Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies 4Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia 2Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia 3Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia 4
... On the tenth anniversary of the completion of the first draft ... years to complete the Wellcome Trust today launches a project ... years. This will be one of the largest genome sequencing programmes ... one in 6,000 people in the UK. The UK10K project ...
... This release is available in German . ... Houbara bustards - a North African bird species with ... visual stimulation from attractive males of the same species ... that observed highly displaying male birds in the experiment ...
... Technology (NIST) scientists have moved a step closer to developing ... scan for thousands of disease markers and other chemical indicators ... decode the electrical signals generated by a nanoporea "gate" less ... Nanopores are not new themselves; for more than a decade, ...
Cached Biology News:Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 2Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 3Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Biology Products: